In the BioHarmony Drug Report Database

"Preview" Icon

Siponimod

Mayzent (siponimod) is a small molecule pharmaceutical. Siponimod was first approved as Mayzent on 2019-03-26. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis. The pharmaceutical is active against sphingosine 1-phosphate receptor 1 and sphingosine 1-phosphate receptor 5. In addition, it is known to target sphingosine 1-phosphate receptor 4 and sphingosine 1-phosphate receptor 3. Mayzent’s patents are valid until 2030-11-30 (FDA).

 

Trade Name

 

Mayzent
 

Common Name

 

siponimod
 

ChEMBL ID

 

CHEMBL2336071
 

Indication

 

relapsing-remitting multiple sclerosis
 

Drug Class

 

Immunomodulators

Image (chem structure or protein)

Siponimod structure rendering